Triplet Regimen of Metronomic Capecitabine Plus Antiangiogenic Drug and PD‐1 Inhibitor as Later‐Line Salvage Treatment for Patients With MSS/pMMR Metastatic Colorectal Cancer: A Retrospective Study

ABSTRACT Later‐line treatment has demonstrated limited survival benefits in patients with metastatic colorectal cancer (mCRC). This retrospective study evaluated the efficacy and safety of a triplet regimen combining metronomic capecitabine, antiangiogenic drugs, and PD‐1 inhibitors in patients with...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Qiong Yang, Yuan‐Yuan Huang, Kai‐Cong Zhang, Qiu‐Sheng Lan, Jie‐Peng Liang, Hui‐Xin Xu, Ya‐Jing Liu, Jing‐Shu Wang, Hui‐Min Liang, He‐Rui Yao, Zhong‐Hua Chu, Hai Hu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2025-07-01
coleção:	MedComm
Assuntos:	immunotherapy metastatic colorectal cancer (mCRC) metronomic chemotherapy microsatellite stable/mismatch repair proficient (MSS/pMMR) targeted therapy
Acesso em linha:	https://doi.org/10.1002/mco2.70174
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!